NaiyerARizviMD

Oncology • New York, NY

Thoracic Cancer

Professor of Medicine, Columbia University Medical Center

Join to view full profile

Dr. Rizvi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Rizvi's full profile

Already have an account?

Office
161 Fort Washington Ave
New York, NY 10032
Phone+1 212-305-3997

Fax+1 212-305-3035
Is this information wrong?

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1995
University of ManitobaClass of 1987

Certifications & Licensure

NY State Medical License 2002 - 2025
VA State Medical License 1996 - 2002
DC State Medical License 1995 - 2002

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2008-2014

Clinical Trials

Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases Start of enrollment: 1999 Jul 01
Completed
Phase 1
10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors Start of enrollment: 2001 May 01
Completed
Phase 1
ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2003 Sep 01
Completed
Phase 1, Phase 2
Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy Start of enrollment: 2003 Dec 01
Completed
Phase 2
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Mar 01
Completed
Phase 1
Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene Start of enrollment: 2004 Jun 01
Completed
Phase 2
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Start of enrollment: 2015 Jun 17
Completed
Phase 1, Phase 2
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer Start of enrollment: 2015 Jul 01
Completed
Phase 1
Genetic Predictors of Benefit to Pembrolizumab Start of enrollment: 2016 May 31
Terminated
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) Start of enrollment: 2019 Mar 11
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
Sanja Dacic, William Travis, Mary Redman, Anjali Saqi, Wendy A Cooper, Alain Borczuk, Jin-Haeng Chung, Carolyn Glass, Javier Martin Lopez, Anja C Roden, Lynette Sholl,...> ;Journal of Thoracic Oncology. 2023 Oct 1
1 citations
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development.
Harriet M Kluger, Hussein Tawbi, David Feltquate, Theresa LaVallee, Naiyer A Rizvi, Elad Sharon, Jeffrey Sosman, Ryan J Sullivan> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
12 citations
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Gr...> ;Nature Genetics. 2023 May 1
5 citations
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Naiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, Helen X Chen, Robert L Ferris, Sarah B Goldberg, Matthew D Hellmann, Ranee Mehra, Jong Chul Park, Harriet Kluger, Hu...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
6 citations
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy.
Rohan Maniar, Peter H Wang, Robert S Washburn, Radomir Kratchmarov, Shana M Coley, Anjali Saqi, Samuel S Pan, Jianhua Hu, Catherine A Shu, Naiyer A Rizvi, Brian S Heni...> ;Cancer Immunology Research. 2023 Feb 3
18 citations
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.
Shoiab Bukhari, Brian S Henick, Robert J Winchester, Shalom Lerrer, Kieran Adam, Yevgeniya Gartshteyn, Rohan Maniar, Ziyan Lin, Alireza Khodadadi-Jamayran, Aristotelis...> ;Cell Reports. Medicine. 2023 Jan 17
4 citations
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
Laurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, Matthew D Hellmann, Sabine Maier, Wendy Hayes, Hao Yang, Pingzhen Guo, Tito Fojo, Lawrence H Schwartz, Binsheng Zha...> ;Journal of Thoracic Oncology. 2023 May 1
7 citations
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications.
Mario Sznol, Naiyer Rizvi> ;Journal for Immunotherapy of Cancer. 2023 Jan 1
21 citations
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
Gilberto de Castro Jr, Naiyer A Rizvi, Peter Schmid, Konstantinos Syrigos, Claudio Martin, Nobuyuki Yamamoto, Ying Cheng, Vladimir Moiseyenko, Yvonne Summers, Ihor Vyn...> ;Journal of Thoracic Oncology. 2023 Jan 1
15 citations
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Je...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
20 citations
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E B...> ;Journal for Immunotherapy of Cancer. 2022 Aug 1
7 citations
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.
Anjali Saqi, Kevin O Leslie, Andre L Moreira, Sylvie Lantuejoul, Catherine Ann Shu, Naiyer A Rizvi, Joshua R Sonett, Kosei Tajima, Shawn W Sun, Barbara J Gitlitz, Thom...> ;JTO Clinical and Research Reports. 2022 May 1
23 citations
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP s...
Natasha B. Leighl, Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William J. Irvin, Sreekanth Reddy, Jeffrey Cra...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
54 citations
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si, M. Kuziora, Katie Quinn, Elena Helman, Jiabu Ye, F. Liu, U. Scheuring, Solange Peters, Naiyer A. Rizvi, Philip Z Brohawn, Koustubh Ranade, Brandon Higgs, Kimbe...> ;Clinical Cancer Research. 2021 Mar 15
10 citations
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (M...
Edward B. Garon, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Gilles Robinet, Sylvestre Le Moulec, Ronald B. Natale, Jeffrey Gary Schn...> ;Clinical Lung Cancer. 2021 Feb 19
102 citations
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
Meagan Montesion, Karthikeyan Murugesan, Dexter X. Jin, Radwa Sharaf, Nora Sanchez, Ameet Guria, Max Minker, Gerald Li, Virginia Fisher, Ethan Sokol, Dean Pavlick, Jay...> ;Cancer Discovery. 2021 Feb 1
13 citations
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.
Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, Kartik Sehgal, Adam Miller, Kenneth L. Kehl, Deepti Venkatraman, Jacob Sands, Giuseppe Lamberti, Gonzalo Recondo,...> ;JTO Clinical and Research Reports. 2020 Nov 1
28 citations
Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors
Bonnie S. Glisson, Rom Leidner, Robert L. Ferris, John D. Powderly, Naiyer A. Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James Ohr, Jennifer Burton, Yanan Zheng...> ;Clinical Cancer Research. 2020 Oct 15
29 citations
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors.
Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael S. Gordon, Philip Mallinder...> ;Clinical Cancer Research. 2020 Dec 1
35 citations
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
Norah J. Shire, Alyssa B Klein, Asieh Golozar, Jenna Collins, Kathy H. Fraeman, Beth L. Nordstrom, Robert McEwen, Todd Hembrough, Naiyer A. Rizvi> ;Plos One. 2020 Sep 3
31 citations
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
Marina Chiara Garassino, Byoung Chul Cho, Joo Hang Kim, Julien Mazieres, Johan Vansteenkiste, Hervé Lena, Jesus Corral Jaime, Jhanelle E. Gray, John D. Powderly, Chris...> ;Lung Cancer. 2020 Sep 1
6 citations
Characteristics and outcomes of lung cancer in solid organ transplant recipients.
Lanyi Nora Chen, John H Spivack, Thu Cao, Anjali Saqi, Luke Benvenuto, William A. Bulman, Matthen Mathew, Mark B. Stoopler, Selim M. Arcasoy, Bryan P. Stanifer, Naiyer...> ;Lung Cancer. 2020 Jun 20
8 citations
Synchronous Pulmonary Adenocarcinomas
Carlos A. Pagan, Catherine A. Shu, John P. Crapanzano, Galina G Lagos, Mark B. Stoopler, Naiyer A. Rizvi, Jonas J. Heymann, Joshua R. Sonett, Helen Fernandes, Anjali Saqi> ;American Journal of Clinical Pathology. 2020 Jun 8
317 citations
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Catherine A. Shu, Justin F. Gainor, Mark M. Awad, Codruta Chiuzan, Claud Grigg, Aliyah Pabani, Robert Garofano, Mark B. Stoopler, Simon K. Cheng, Abby White, Michael L...> ;The Lancet. Oncology. 2020 Jun 1
383 citations
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinic...
Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel M. van den Heuvel, M. Cobo, David Vicente, Alexey Smolin, Vladimi...> ;JAMA Oncology. 2020 May 1
Join now to see all

Journal Articles

Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)
Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences

Lectures

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy ...
2019 ASCO Annual Meeting - 6/1/2019
Lung Cancer. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1)
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

As Biotech Debates Vaccine Mandates, One CEO Tries to Convince the 3% That Got AwayAugust 11th, 2021
Synthekine Scores Major $108M B Round to Secure Set of Trials in 12 MonthsJune 10th, 2021
Investors Pile on Stanford Spinout Promising New Ways to Attack Cancer, Autoimmune DiseasesJune 10th, 2021
Join now to see all

Grant Support

Early Clinical Trials Of New Anti-Cancer Agents With Phase 1 EmphasisNational Cancer Institute2008
Phase I Clinical Trials Of Novel AgentsNational Cancer Institute2006–2007
Foreign Accrual For 5u10ca069856 2006 Load Phase I U01 Rizvi MskiNational Cancer Institute2006
Correlation Of EGFR Mutations And Response To GefitinibNational Cancer Institute2005–2006
Pv701 Safety/Efficacy In Advanced/Recurrent Solid TumorsNational Center For Research Resources2000
Oral Dose Escalation Of Tac-101 In Advanced MalignanciesNational Center For Research Resources2000
Oral BMS-275291 Metalloproteinase Inhibitor In CancerNational Center For Research Resources2000

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York
New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York